In 2023, pancreatic cancer transitioned from being a rare form to a common cancer in Australia—a troublesome statistic, seeing as…
Noxopharm (ASX: NOX) will hopefully see an increase in value of their flagship drug following this morning’s announcement. The Company has…
Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds,…
Prostate cancer patients could soon be in for potentially good news after clinical stage-drug development company, Noxopharm (ASX: NOX) reported…